(OFIX) Orthofix Medical - Ratings and Ratios
Bone Stimulators, Spine Implants, Biologics, Navigation Systems, Limb Fixation
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 43.7% |
| Value at Risk 5%th | 64.4% |
| Relative Tail Risk | -10.56% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.27 |
| Alpha | -27.96 |
| CAGR/Max DD | -0.17 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.448 |
| Beta | 0.883 |
| Beta Downside | 1.109 |
| Drawdowns 3y | |
|---|---|
| Max DD | 57.43% |
| Mean DD | 31.42% |
| Median DD | 32.10% |
Description: OFIX Orthofix Medical December 27, 2025
Orthofix Medical Inc. (NASDAQ:OFIX) is a U.S.–based medical-technology firm that designs, manufactures, and distributes spine- and orthopedics-focused devices across North America, Europe, and Brazil. The company operates two business lines: Global Spine, which offers bone-growth stimulators, fixation and motion-preservation implants, biologics, and a 7D flash navigation platform for spine and cranial surgery; and Global Orthopedics, which supplies external and internal fixation systems for limb reconstruction and deformity correction, all integrated with digital workflow tools.
In FY 2023 the company generated roughly $210 million in revenue, with the Global Spine segment contributing about 70 % of sales, while the Global Orthopedics segment accounted for the remainder. Orthofix’s revenue growth has been modest (≈3 % YoY) and the firm continues to post a net loss, reflecting ongoing R&D spend and the need to scale its digital navigation solutions. The firm employs roughly 600 staff and sells primarily through a mix of direct sales reps and regional distributors to hospitals and health-system networks.
Key market drivers include an aging population that is expanding the global spine-device market at a projected CAGR of 6 % through 2030, and increasing adoption of image-guided and robot-assisted surgical technologies that Orthofix’s 7D navigation system targets. Reimbursement trends under Medicare and private insurers also shape product pricing and adoption rates, making payer policy a critical economic factor for the company.
For a deeper quantitative view, you may explore the OFIX profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-119.1m TTM) > 0 and > 6% of Revenue (6% = 49.1m TTM) |
| FCFTA -0.00 (>2.0%) and ΔFCFTA 5.11pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 28.64% (prev 28.60%; Δ 0.04pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 29.4m > Net Income -119.1m (YES >=105%, WARN >=100%) |
| Net Debt (138.5m) to EBITDA (5.26m) ratio: 26.32 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.47 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (39.8m) change vs 12m ago 3.32% (target <= -2.0% for YES) |
| Gross Margin 68.27% (prev 68.05%; Δ 0.22pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 96.21% (prev 90.36%; Δ 5.85pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -3.22 (EBITDA TTM 5.26m / Interest Expense TTM 28.1m) >= 6 (WARN >= 3) |
Altman Z'' -1.27
| (A) 0.28 = (Total Current Assets 394.2m - Total Current Liabilities 159.8m) / Total Assets 832.6m |
| (B) -0.44 = Retained Earnings (Balance) -366.1m / Total Assets 832.6m |
| (C) -0.11 = EBIT TTM -90.3m / Avg Total Assets 850.2m |
| (D) -0.93 = Book Value of Equity -361.5m / Total Liabilities 390.1m |
| Total Rating: -1.27 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 37.55
| 1. Piotroski 3.50pt |
| 2. FCF Yield -0.39% |
| 3. FCF Margin -0.35% |
| 4. Debt/Equity 0.46 |
| 5. Debt/Ebitda 26.32 |
| 6. ROIC - WACC (= -22.36)% |
| 7. RoE -25.59% |
| 8. Rev. Trend 86.32% |
| 9. EPS Trend -39.81% |
What is the price of OFIX shares?
Over the past week, the price has changed by -1.61%, over one month by -5.28%, over three months by +6.13% and over the past year by -12.91%.
Is OFIX a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the OFIX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.8 | 49.6% |
| Analysts Target Price | 22.8 | 49.6% |
| ValueRay Target Price | 15 | -1.9% |
OFIX Fundamental Data Overview December 27, 2025
P/E Forward = 31.5457
P/S = 0.7338
P/B = 1.3567
P/EG = 3.1578
Beta = 0.822
Revenue TTM = 818.1m USD
EBIT TTM = -90.3m USD
EBITDA TTM = 5.26m USD
Long Term Debt = 157.2m USD (from longTermDebt, last quarter)
Short Term Debt = 3.97m USD (from shortTermDebt, last quarter)
Debt = 204.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 138.5m USD (from netDebt column, last quarter)
Enterprise Value = 738.9m USD (600.3m + Debt 204.5m - CCE 65.9m)
Interest Coverage Ratio = -3.22 (Ebit TTM -90.3m / Interest Expense TTM 28.1m)
FCF Yield = -0.39% (FCF TTM -2.90m / Enterprise Value 738.9m)
FCF Margin = -0.35% (FCF TTM -2.90m / Revenue TTM 818.1m)
Net Margin = -14.56% (Net Income TTM -119.1m / Revenue TTM 818.1m)
Gross Margin = 68.27% ((Revenue TTM 818.1m - Cost of Revenue TTM 259.5m) / Revenue TTM)
Gross Margin QoQ = 72.23% (prev 68.69%)
Tobins Q-Ratio = 0.89 (Enterprise Value 738.9m / Total Assets 832.6m)
Interest Expense / Debt = 2.29% (Interest Expense 4.68m / Debt 204.5m)
Taxrate = -2.39% (negative due to tax credits) (533.0k / -22.3m)
NOPAT = -92.4m (EBIT -90.3m * (1 - -2.39%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 2.47 (Total Current Assets 394.2m / Total Current Liabilities 159.8m)
Debt / Equity = 0.46 (Debt 204.5m / totalStockholderEquity, last quarter 442.5m)
Debt / EBITDA = 26.32 (Net Debt 138.5m / EBITDA 5.26m)
Debt / FCF = -47.77 (negative FCF - burning cash) (Net Debt 138.5m / FCF TTM -2.90m)
Total Stockholder Equity = 465.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.31% (Net Income -119.1m / Total Assets 832.6m)
RoE = -25.59% (Net Income TTM -119.1m / Total Stockholder Equity 465.6m)
RoCE = -14.49% (EBIT -90.3m / Capital Employed (Equity 465.6m + L.T.Debt 157.2m))
RoIC = -14.85% (negative operating profit) (NOPAT -92.4m / Invested Capital 622.6m)
WACC = 7.51% (E(600.3m)/V(804.8m) * Re(9.27%) + D(204.5m)/V(804.8m) * Rd(2.29%) * (1-Tc(-0.02)))
Discount Rate = 9.27% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.34%
Fair Price DCF = unknown (Cash Flow -2.90m)
EPS Correlation: -39.81 | EPS CAGR: -7.99% | SUE: 1.12 | # QB: 1
Revenue Correlation: 86.32 | Revenue CAGR: 14.18% | SUE: 2.22 | # QB: 4
EPS next Quarter (2026-03-31): EPS=-0.14 | Chg30d=-0.010 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.42 | Chg30d=-0.030 | Revisions Net=+1 | Growth EPS=-39.1% | Growth Revenue=+5.4%
Additional Sources for OFIX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle